Baseline Demographics, Clinical Characteristics, Treatment Patterns, and Burden of Atopic Dermatitis in Patients Initiating Dupilumab: A Retrospective, Observational Study Using Data From a Real-World Registry (CORNERSTONE)

IF 1 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2026-08-31 DOI:10.1155/dth/4711988

Jiahui Zhao, Dan Shen, Mingxiao Chen, Joshua Zhang, Ruoyu Li, Yang Wang, Hang Li

{"title":"Baseline Demographics, Clinical Characteristics, Treatment Patterns, and Burden of Atopic Dermatitis in Patients Initiating Dupilumab: A Retrospective, Observational Study Using Data From a Real-World Registry (CORNERSTONE)","authors":"Jiahui Zhao, Dan Shen, Mingxiao Chen, Joshua Zhang, Ruoyu Li, Yang Wang, Hang Li","doi":"10.1155/dth/4711988","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>Chinese atopic dermatitis (AD) patients initiating dupilumab in real-world settings are not well characterized.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To describe baseline characteristics of Chinese AD patients starting dupilumab.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This was a retrospective study utilizing real-world data from the observational registry of China Type 2 Inflammatory Skin Diseases, CORNERSTONE, for AD patients initiating dupilumab.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Between August 2021 and July 2022, 3960 dupilumab users were identified (age: 1–96 years, male: 58.5%). Early-onset AD was noted in 13.2%, with common anatomic sites affected being the trunk, arm, and leg. Clinical phenotypes included typical flexural dermatitis (62.1%), inflammatory (20.2%), and xerosis (15.2%). Type 2 inflammatory comorbidities were present in 50.8%, with allergic rhinitis/sinusitis, food allergy, and bronchial asthma being most prevalent. Topical corticosteroids and antihistamines often precede and accompany dupilumab. Mean Eczema Area and Severity Index (EASI) score was 13.5, Body Surface Area (BSA) affected 29.7%, and Peak Pruritus Numerical Rating Scale (PP-NRS) 7.2. Infants’ Dermatitis Quality of Life index (IDQoL), Children’s Dermatology Life Quality Index (CDLQI), and Dermatology Life Quality Index (DLQI) scores were 16.9, 13.8, and 13.1 for patients < 4, ≥ 4–< 16, and ≥ 16 years, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In China, real-world AD patients initiating dupilumab exhibit a broad age spectrum and clinical characteristics, with multidimensional baseline disease burden.</p>\n </section>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4711988","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/4711988","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Chinese atopic dermatitis (AD) patients initiating dupilumab in real-world settings are not well characterized.

Objective

To describe baseline characteristics of Chinese AD patients starting dupilumab.

Methods

This was a retrospective study utilizing real-world data from the observational registry of China Type 2 Inflammatory Skin Diseases, CORNERSTONE, for AD patients initiating dupilumab.

Results

Between August 2021 and July 2022, 3960 dupilumab users were identified (age: 1–96 years, male: 58.5%). Early-onset AD was noted in 13.2%, with common anatomic sites affected being the trunk, arm, and leg. Clinical phenotypes included typical flexural dermatitis (62.1%), inflammatory (20.2%), and xerosis (15.2%). Type 2 inflammatory comorbidities were present in 50.8%, with allergic rhinitis/sinusitis, food allergy, and bronchial asthma being most prevalent. Topical corticosteroids and antihistamines often precede and accompany dupilumab. Mean Eczema Area and Severity Index (EASI) score was 13.5, Body Surface Area (BSA) affected 29.7%, and Peak Pruritus Numerical Rating Scale (PP-NRS) 7.2. Infants’ Dermatitis Quality of Life index (IDQoL), Children’s Dermatology Life Quality Index (CDLQI), and Dermatology Life Quality Index (DLQI) scores were 16.9, 13.8, and 13.1 for patients < 4, ≥ 4–< 16, and ≥ 16 years, respectively.

Conclusions

In China, real-world AD patients initiating dupilumab exhibit a broad age spectrum and clinical characteristics, with multidimensional baseline disease burden.

查看原文本刊更多论文

基线人口统计学、临床特征、治疗模式和特应性皮炎患者的负担：一项使用真实世界注册数据的回顾性观察性研究（CORNERSTONE）

背景：中国特应性皮炎（AD）患者在现实环境中开始使用dupilumab并没有很好地表征。目的描述中国AD患者开始使用dupilumab的基线特征。方法：这是一项回顾性研究，利用来自中国2型炎症性皮肤病（CORNERSTONE）观察登记的真实数据，对开始使用杜匹单抗的AD患者进行研究。结果在2021年8月至2022年7月期间，确定了3960名dupilumab使用者（年龄：1-96岁，男性：58.5%）。早发性AD占13.2%，常见的解剖部位为躯干、手臂和腿部。临床表型包括典型的屈曲性皮炎（62.1%）、炎症（20.2%）和干燥（15.2%）。50.8%的患者存在2型炎症合并症，其中过敏性鼻炎/鼻窦炎、食物过敏和支气管哮喘最为常见。局部皮质类固醇和抗组胺药通常在dupilumab之前和伴随使用。平均湿疹面积及严重程度指数（EASI）评分为13.5分，体表面积（BSA）评分为29.7%，峰值瘙痒数值评定量表（PP-NRS）评分为7.2分。4岁、≥4 - 16岁、≥16岁患儿皮炎生活质量指数（IDQoL）、儿童皮肤病生活质量指数（CDLQI）、皮肤病生活质量指数（DLQI）评分分别为16.9分、13.8分、13.1分。在中国，现实世界中开始使用dupilumab的AD患者表现出广泛的年龄谱和临床特征，具有多维基线疾病负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.